 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"phenytoin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN: warnings_and_cautions: The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m dose, compliance, concomitant [0m
[31mmedications, comorbidities, and the level of dermatologic monitoring have not been studied. [0m[1;31m5.4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction [0m
[31mwith Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan Hypersensitivity, has been reported in patients taking antiepileptic drugs, including phenytoin. Some of these events have [0m
[31mbeen fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such [0m
[31mas hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. PHENYTOIN: warnings_and_cautions: Because [0m
[31mthis disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or [0m
[31mlymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin Sodium Injection should be discontinued [0m
[31mif an alternative etiology for the signs or symptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin [0m
[31mhypersensitivity [0m[31m . Additionally, consider alternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., carbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and oxazolidinediones [0m[1;31m([0m[31me.g., [0m
[31mtrimethadione[0m[1;31m)[0m[31m in these same patients. PHENYTOIN: warnings_and_cautions: Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in the patient or immediate [0m
[31mfamily members, consider alternatives to phenytoin. [0m[1;31m5.6[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These [0m
[31mevents may be part of the spectrum of DRESS or may occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. [0m
[31mThe clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not [0m
[31mre-administered. [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m7[0m[31m Hematopoietic Complications Hematopoietic complications, some fatal, have occasionally been reported in association with administration of [0m
[31mphenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have been a number of reports suggesting[0m
[31ma relationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a [0m
[31mcause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node [0m
[31minvolvement may occur with or without symptoms and signs resembling DRESS [0m[31m. PHENYTOIN: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated[0m
[31mand every effort should be made to achieve seizure control using alternative antiepileptic drugs. [0m[1;31m5.8[0m[31m Local Toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m Soft tissue irritation and inflammation has [0m
[31moccurred at the site of injection with and without extravasation of intravenous phenytoin. Edema, discoloration and pain distal to the site of injection [0m[1;31m([0m[31mdescribed as â€œpurple glove syndromeâ€[0m[1;31m)[0m[31m have [0m
[31malso been reported following peripheral intravenous phenytoin injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for [0m
[31mseveral days after injection. Although resolution of symptoms may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in [0m
[31mrare cases, amputation. PHENYTOIN: warnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or [0m
[31mcentral vein through a large-gauge catheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium [0m
[31mInjection should then be followed by a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium [0m
[31mInjection administration may cause pain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the [0m
[31mfraction of unbound phenytoin is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction[0m
[31min those patients. [0m[1;31m5.10[0m[31m Exacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients [0m
[31msuffering from this disease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may[0m
[31mincrease the risks for congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN: warnings_and_cautions: Increased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and[0m
[31mcardiac defects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding [0m
[31mmicrocephaly[0m[1;31m)[0m[31m, and cognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have [0m
[31mbeen several reported cases of malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in [0m
[31mnewborns exposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia [0m
[31mHyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic [0m
[31mpatients. [0m[1;31m5.13[0m[31m Serum Phenytoin Levels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m
[31m"encephalopathy"[0m[31m, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction [0m
[31mof phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: pharmacokinetics: Distribution Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Elimination The serum half-life in man after intravenous [0m
[31madministration ranges from [0m[1;31m10[0m[31m to [0m[1;31m15[0m[31m hours. Metabolism Phenytoin is metabolized by the hepatic cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19. Excretion Most of the drug is excreted [0m
[31min the bile as inactive metabolites. Urinary excretion of phenytoin and its metabolites occurs partly by glomerular filtration but, more importantly, by tubular secretion. Specific Populations Age: [0m
[31mGeriatric Population: Phenytoin clearance tends to decrease with increasing age [0m[1;31m([0m[1;31m20[0m[31m% less in patients over [0m[1;31m70[0m[31m years of age relative to that in patients [0m[1;31m20[0m[31m to [0m[1;31m30[0m[31m years of age[0m[1;31m)[0m[31m. PHENYTOIN: [0m
[31mpharmacokinetics: Since phenytoin clearance is decreased slightly in elderly patients, lower or less frequent dosing may be required [0m[31m. S e x [0m[31m/[0m[31mRace[0m[31m: Gender and race have no significant impact on [0m
[31mphenytoin pharmacokinetics. Renal or Hepatic Impairment: Increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with hypoalbuminemia has been reported. P [0m
[31mregnancy: It has been reported in the literature that the plasma clearance of phenytoin generally increased during pregnancy, reached a peak in the third trimester and returned to the level of [0m
[31mpre-pregnancy after few weeks or months of delivery. Drug Interaction Studies Phenytoin is primarily metabolized by the cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19. PHENYTOIN: [0m
[31mpharmacokinetics: Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes [0m[31m .         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse [0m
[31mdevelopmental outcomes. [0m[1;31m([0m[31m [0m[1;31m5.11[0m[31m , [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure [0m
[31mRegistry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as Phenytoin Sodium Injection, during pregnancy. Physicians are [0m
[31madvised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry. This can be done by calling the toll free number [0m
[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. PHENYTOIN: use_in_specific_populations: Information on the registry can also be found at the website [0m[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . [0m
[31mRisk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal phenytoin exposure is associated with an [0m
[31mincreased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. In addition, the fetal hydantoin syndrome a pattern of abnormalities including dysmorphic skull and facial [0m
[31mfeatures, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to epileptic women who took phenytoin alone or in [0m
[31mcombination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in children whose mothers received phenytoin during [0m
[31mpregnancy. PHENYTOIN: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other manifestations of developmental [0m
[31mtoxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general population, the estimated background risk[0m
[31mof major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. The background risk of major birth defects and miscarriage for the indicated [0m
[31mpopulation is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic [0m
[31mmeasurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage [0m[31m . However, postpartum restoration of the original [0m
[31mdosage will probably be indicated. PHENYTOIN: use_in_specific_populations: Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to decreased levels of vitamin [0m
[31mK-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the [0m
[31mneonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately [0m[1;31m2.4[0m[31m-fold increased risk for any major malformation in [0m
[31mchildren with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia has been reported. The fetal hydantion syndrome is a pattern [0m
[31mof congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and neurodevelopmental deficiencies.         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: use_in_specific_populations: Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, [0m
[31mand decreased fetal growth retardation. Malformations [0m[1;31m([0m[31mincluding craniofacial, cardiovascular, neural, limb, and digit abnormalities[0m[1;31m)[0m[31m were observed in rats, rabbits, and mice at doses as low as [0m[1;31m100[0m[31m, [0m
[1;31m75[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg, respectively. [0m[1;31m8.2[0m[31m Lactation Risk Summary Phenytoin is secreted in human milk. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s [0m
[31mclinical need for Phenytoin Sodium Injection and any potential adverse effects on the breastfed infant from Phenytoin Sodium Injection or from the underlying maternal condition. [0m[1;31m8[0m[31m. PHENYTOIN: [0m
[31muse_in_specific_populations: [0m[1;31m4[0m[31m Pediatric Use A loading dose of [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m mg/kg of Phenytoin Sodium Injection intravenously will usually produce serum concentrations of phenytoin within the generally [0m
[31maccepted serum total concentrations between [0m[1;31m10[0m[31m and [0m[1;31m20[0m[31m mcg/mL [0m[1;31m([0m[31munbound phenytoin concentrations of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mcg/mL[0m[1;31m)[0m[31m. Because of the increased risk of adverse cardiovascular reactions associated with [0m
[31mrapid administration Phenytoin Sodium Injection should be injected slowly intravenously at a rate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower [0m[31m. [0m[1;31m8.5[0m[31m Geriatric Use Phenytoin [0m
[31mclearance tends to decrease with increasing age [0m[31m . Lower or less frequent dosing may be required [0m[31m. [0m[1;31m8[0m[31m. PHENYTOIN: use_in_specific_populations: [0m[1;31m6[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia The [0m
[31mliver is the site of biotransformation. Patients with impaired liver function, elderly patients, or those who are gravely ill may show early toxicity. Because the fraction of unbound phenytoin is [0m
[31mincreased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m8.7[0m[31m Use in [0m
[31mPatients with Decreased CYP2C9 Function Patients who are intermediate or poor metabolizers of CYP2C9 substrates [0m[1;31m([0m[31me.g.,*[0m[1;31m1[0m[31m/*[0m[1;31m3[0m[31m, *[0m[1;31m2[0m[31m/*[0m[1;31m2[0m[31m, *[0m[1;31m3[0m[31m/*[0m[1;31m3[0m[1;31m)[0m[31m may exhibit increased phenytoin serum concentrations compared[0m
[31mto patients who are normal metabolizers [0m[1;31m([0m[31me.g., *[0m[1;31m1[0m[31m/*[0m[1;31m1[0m[31m [0m[1;31m)[0m[31m. PHENYTOIN: use_in_specific_populations: Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses [0m
[31mof phenytoin to maintain similar steady-state concentrations compared to normal metabolizers. If early signs of dose-related central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m toxicity develop, serum concentrations should [0m
[31mbe checked immediately [0m[31m .         [0m
[31mSOURCE:PHENYTOIN label[0m


[31mCONTENT: PHENYTOIN: adverse_reactions: [0m[1;31m8[0m[1;31m)[0m[31m [0m[1;31m][0m[31m Exacerbation of Porphyria [0m[31m Teratogenicity and Other Harm to the Newborn [0m[31m Hyperglycemia [0m[31m The following adverse reactions associated with the use of Phenytoin[0m
[31mSodium Injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to [0m
[31mreliably estimate their frequency or establish a causal relationship to drug exposure. The most notable signs of toxicity associated with the intravenous use of this drug are cardiovascular collapse [0m
[31mand/or CNS depression. Hypotension does occur when the drug is administered rapidly by the intravenous route. PHENYTOIN: adverse_reactions: The rate of administration is very important; it should not [0m
[31mexceed [0m[1;31m50[0m[31m mg per minute in adults, and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients [0m[31m . Body As a Whole: Allergic reactions in the form of rash and rarely more [0m
[31mserious forms [0m[1;31m([0m[31msee Skin and Appendages paragraph below[0m[1;31m)[0m[31m and DRESS [0m[31m have been observed. Anaphylaxis has also been reported. There have also been reports of coarsening of facial features, systemic lupus[0m
[31merythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe cardiovascular events and fatalities have been reported with atrial and ventricular conduction depression [0m
[31mand ventricular fibrillation. PHENYTOIN: adverse_reactions: Severe complications are most commonly encountered in elderly or critically ill patients [0m[31m . Digestive System: Acute hepatic failure [0m[31m , toxic[0m
[31mhepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. Hematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally[0m
[31mbeen reported in association with administration of phenytoin [0m[31m . These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow [0m
[31msuppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. PHENYTOIN: adverse_reactions: Lymphadenopathy, including benign lymph [0m
[31mnode hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease have been reported [0m[31m. Laboratory Test Abnormality: Phenytoin may decrease serum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, [0m
[31msometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in the absence of clinical hypothyroidism. Phenytoin may also produce lower than normal values for [0m
[31mdexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of glucose , alkaline phosphatase, and gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse [0m
[31mreactions encountered with phenytoin therapy are nervous system reactions and are usually dose-related. PHENYTOIN: adverse_reactions: Reactions include nystagmus, ataxia, slurred speech, decreased [0m
[31mcoordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor twitchings, paresthesia, and headaches have also been observed. There have also been rare [0m
[31mreports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs. Cerebellar atrophy has been reported,[0m
[31mand appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use [0m[31m . A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term [0m
[31mphenytoin therapy. Sk in and Appendages: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes.         [0m
[31mSOURCE:PHENYTOIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, PHENYTOIN can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events [0m
[32mmay be part of the spectrum of DRESS [0m[1;32m([0m[32mDrug Reaction with Eosinophilia and Systemic Symptoms[0m[1;32m)[0m[32m or may occur in isolation. Common manifestations include jaundice, hepatomegaly, elevated serum [0m
[32mtransaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In patients with acute hepatotoxicity, [0m
[32mphenytoin should be immediately discontinued and not re-administered.[0m

[32mSOURCE: PHENYTOIN label[0m
[32mEXTRACT_START_END: Cases of acute hepatotoxicity[0m[32m...[0m[32m not re-administered.[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, PHENYTOIN can increase the risk of acute liver injury. [0m
[34mCases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events may be part of the spectrum of DRESS [0m[1;34m([0m[34mDrug Reaction with [0m
[34mEosinophilia and Systemic Symptoms[0m[1;34m)[0m[34m or may occur in isolation. Common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical [0m
[34mcourse of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered.[0m

[34mSOURCE: PHENYTOIN label[0m
[34mEXTRACT_START_END: Cases of acute hepatotoxicity[0m[34m...[0m[34m not re-administered.[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if PHENYTOIN increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that PHENYTOIN can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with [0m
[32mphenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with common manifestations such as jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and[0m
[32meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"PHENYTOIN can increase the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if PHENYTOIN increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that PHENYTOIN can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with [0m
[34mphenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with common manifestations such as jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and[0m
[34meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"PHENYTOIN can increase the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if PHENYTOIN increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler confirmed that PHENYTOIN can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with [0m
[31mphenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with common manifestations such as jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and[0m
[31meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued.[0m
[31m        -----[0m
[31m        Final answer: PHENYTOIN can increase the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mPHENYTOIN can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events may be part [0m
[32mof the spectrum of DRESS [0m[1;32m([0m[32mDrug Reaction with Eosinophilia and Systemic Symptoms[0m[1;32m)[0m[32m or may occur in isolation. Manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, [0m
[32mleukocytosis, and eosinophilia. The clinical course can range from prompt recovery to fatal outcomes. In cases of acute hepatotoxicity, phenytoin should be immediately discontinued and not [0m
[32mre-administered.[0m
